Development and Evaluation of AS04, a Novel and Improved Adjuvant System Containing 3-O-Desacyl-4′- Monophosphoryl Lipid A and Aluminum Salt

During the past two decades, GSK Vaccines has been developing new Adjuvant Systems (ASs) intended to promote a faster, stronger, and longer protection through the induction of high and persistent antibody titer and induction of cell-mediated immunity (CMI). One such proprietary AS, AS04, has been developed for prophylactic vaccines. AS04 is composed of two adjuvants: aluminum salt and 3-O-desacyl-4′- monophosphoryl lipid A (MPL).